DEVONIAN HEALTH GROUP INC.
For immediate release
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Devonian Announces Issuance of One New Key Patent
and the Granting of a Trademark.
QUEBEC, June 21, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD) a
clinical stage botanical pharmaceutical corporation, announces today that the U.S. Patent and Trademark
Office has recently issued Patent #9,555,068, entitled ‘‘Oral compositions and route of administration
for the delivery of a thylakoid extract’’. The patent covers the oral delivery of thylakoid extract for
treating or preventing a disease or disorder involving the formation of reactive oxygen species and
inflammation in individuals. The patent also covers the use of thylakoids as a food or a food supplement,
as a pellet, as encapsulated granules or powder.
“We are very excited to have received additional patent protection covering oral delivery of thylakoids.
The new patent covers several delivery formulations of thylakoids, the active ingredient of our lead
product Thykamine™,” said Dr Andre P. Boulet, President & CEO of Devonian”
The Corporation also announces that the U.S. Patent and Trademark Office has recently granted a
trademark for R-Spinasome®, the active ingredient of its Purgenesis™ derma-cosmetic products.
“The granting of a trademark to R-Spinasome®, the active ingredient of our Purgenesis™ anti-aging
treatment (patent-pending), has a significant impact within our Intellectual Property (IP) strategy. Our IP
strategy includes patents and trademarks as a pair in order to provide higher economic value to our
shareholders. We apply this strategy to our pharmaceutical and derma-cosmeceutical programs. ’’ adds
ThykamineTM, the first pharmaceutical product issued from Devonian’s SUPREXTM platform is a highly
innovative product to be used in the prevention and treatment of health conditions related to inflammation
and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, skin
aging, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory
properties of ThykamineTM have been demonstrated by an impressive number of in vitro and in
vivo studies as well as in a Phase 2a clinical study in patients with mild-to-moderate distal ulcerative
colitis. ThykamineTM is currently under development for ulcerative colitis and atopic dermatitis. Both
ThykamineTM and SUPREXTM platform are protected by several patents in North America, Europe and
About PurGenesis™ anti-aging treatment
PurGenesis™ anti-aging treatment has three components: a day cream, a night cream and an eye
cream. These creams contain R-Spinasome® complex, an active structure of pigments, proteins and
lipids extracted from organic baby spinach. The structure of this complex is critical to its function as an
anti-oxidant, enabling it to capture and dissipate noxious energy generated by Reactive Oxygen Species
(ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this
dynamism and capacity to regenerate that provides R-Spinasome® complex with unprecedented, longlasting
anti-oxidant activity. A clinical study involving 72 subjects (aged 35-72years) was conducted to
evaluate the performance of Purgenesis™ Anti-aging product line compared with two other leading
prestige brands over a 28 day period of use. The results indicate that PurGenesis™ anti-aging line is
significantly superior than leading prestige brands in terms of its anti-wrinkle, firmness and hydration
effects. PurGenesis™ anti-aging treatment is patent-pending worldwide with the exception of Japan
where a patent was issued (#JP 5952261).
Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches
targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This
strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development
pathway versus traditional prescription medicines. Devonian is based on a broad-based platform
originating from over ten years of research. This platform provides a unique process of extraction,
purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic
process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology
(SUPREX). The “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory
and anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments
as well as in a Phase 2a “proof of concept” clinical study in patients with mild-to-moderate distal ulcerative
colitis. The product is now moving into large phase 2 clinical trials in two therapeutic areas: Ulcerative
Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business,
Devonian is also involved in the development of high value derma-cosmeceutical products as part of a
secondary strategy to generate short-term revenues and optimize manufacturing efficiency.
Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and
businesses that involve risks and uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to
be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical
products, the availability of funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the
pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current expectations in Devonian’s prospectus
dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a result of future events or
for any other reason, unless required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
President and Chief Executive Officer
Devonian Health Group inc.
Telephone: (514) 248-7509